{"id":3197,"date":"2022-01-01T12:01:07","date_gmt":"2022-01-01T11:01:07","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=3197"},"modified":"2022-04-04T13:54:20","modified_gmt":"2022-04-04T11:54:20","slug":"neue-lipidsenker-teil-2-evinacumab","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/neue-lipidsenker-teil-2-evinacumab","title":{"rendered":"Neue Lipidsenker Teil 2: Evinacumab [CME]"},"content":{"rendered":"<p>Evinacumab (Evi) ist ein monoklonaler Antik\u00f6rper mit neuartigem, sog. \u201efirst in class\u201c-Wirkmechanismus. Das LDL-Cholesterin (LDL-C) im Blut wird unabh\u00e4ngig von den LDL-C-Rezeptoren gesenkt. Evi bindet an das hepatozellul\u00e4re Angiopoietin-like-3-Protein (ANGPTL3) und hemmt dessen Funktion (ANGPTL3-Inhibitor; ). ANGPTL3 fungiert u.a. als Inhibitor der Lipoproteinlipase und der endothelialen Lipase, die f\u00fcr die Entstehung von LDL aus VLDL [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evinacumab (Evi) ist ein monoklonaler Antik\u00f6rper mit neuartigem, sog. \u201efirst in class\u201c-Wirkmechanismus. Das LDL-Cholesterin (LDL-C) im Blut wird unabh\u00e4ngig von den LDL-C-Rezeptoren gesenkt. Evi bindet an das hepatozellul\u00e4re Angiopoietin-like-3-Protein (ANGPTL3) und hemmt dessen Funktion (ANGPTL3-Inhibitor; ). ANGPTL3 fungiert u.a. als Inhibitor der Lipoproteinlipase und der endothelialen Lipase, die f\u00fcr die Entstehung von LDL aus VLDL [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,60,1272,255,1274,5616,5510,71,68,453,498,456,257,65,56],"class_list":["post-3197","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-apoplektischer-insult","tag-arteriosklerose","tag-arzneimittel","tag-cholesterin","tag-elipse-hofh-studie","tag-evinacumab","tag-herzinfarkt","tag-hirninfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-medikamente","tag-myokardinfarkt","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=3197"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3197\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=3197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=3197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=3197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}